JENSCARE-B(09877)

3.920+0.110+2.89%

Market data delayed 15 minutes

    • 4c003ce9
      ·
      2024-08-28

      Jenscare 2024H1 Interim Result

      Financial Highlights: Net Loss Narrowed Significantly with Solid Cash Balance Jenscare (9877.HK), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, released interim results for 2024H1 ended June 30, 2024. Net Loss attributable to common shareholders was RMB 102 million[1] (US$ 14 million), narrowed down by 41.8% compared to the same period of last year. Cash[2] was RMB 922 million (US$ 129 million), which is sufficient for the future development of the Company to achieve its business strategy by advancing the global application of its Core Products, including carrying forward the clinical trial, the registration process, and market launch of the products. [1] Conversions from RMB to US$ is made at an excha
      Jenscare 2024H1 Interim Result
      Comment
      Report
      4c003ce9
      ·
      2024-01-08

      Jenscare (9877.HK) 2023Q4 Newsletter

      Disclaimer The information disclosed in this article is for academic communication purposes only and should not be construed as medical advice under any circumstances. We make no representations or warranties as to the accuracy, completeness or timeliness of all original, reproduced or shared content.  For any medical device mentioned in this article, our company does not make any commitment and guarantee on its performance and clinical performance in diagnosis and treatment activities. $健世科技-B(09877)$
      Jenscare (9877.HK) 2023Q4 Newsletter
      Comment
      Report
      4c003ce9
      ·
      2023-10-13

      Jenscare(9877.HK) 2023Q3 Newsletter

      Jenscare(9877.HK) 2023Q3 Newsletter Jenscare(9877.HK) 2023Q3 Newsletter $健世科技-B(09877)$
      Jenscare(9877.HK) 2023Q3 Newsletter
      Comment
      Report
      4c003ce9
      ·
      2023-07-17

      Jenscare 2023Q2 Newsletter

      Jenscare(9877.HK) 2023Q2 Newsletter $健世科技-B(09877)$
      Jenscare 2023Q2 Newsletter
      Comment
      Report
    • Company Profile

      Company Name
      JENSCARE-B
      Market
      SEHK
      Establishment Date
      - -
      Employees
      - -
      Office Location
      - -
      Zip Code
      - -
      Phone
      - -
      Fax
      - -
      Introduction
      Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The Company develops interventional products for the treatment of structural heart disease. The Company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The Company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. The Company mainly conducts its businesses in the domestic market.
      • 1D
      • 5D
      • Day
      • Week
      • Month
      Loading ...
      High
      4.180
      Open
      4.180
      Volume%
      0.27
      Low
      3.910
      Close
      3.810
      T/O Rate
      0.01%
      errorbox banner

      抱歉,当前请求异常(-1)

      Company: TTMF Limited. Tech supported by Xiangshang Yixin.

      Email:uservice@ttm.financial